3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Cyclophosphamide
27
fludarabine
18
Rituximab
17
obinutuzumab
11
venetoclax
9
Bendamustine Hydrochloride
9
Lenalidomide
8
zanubrutinib
6
Prednisone
6
Doxorubicin
6
Blood Specimen Collection
6
pembrolizumab
5
fludarabine phosphate
5
Biopsy
5
ibrutinib
4
glofitamab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Exercise
4
loncastuximab tesirine
3
gamma-Globulins
3
axicabtagene ciloleucel
3
acalabrutinib
3
Temozolomide
3
Surveys and Questionnaires
3
Palliative Care
3
Mycophenolic Acid
3
Methotrexate
3
Mesna
3
Magnetic Resonance Spectroscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma
×
amino-acid, glucose, and electrolyte solution
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled